GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (FRA:7EY) » Definitions » Shiller PE Ratio

Kiora Pharmaceuticals (FRA:7EY) Shiller PE Ratio : (As of Jun. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kiora Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kiora Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Kiora Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Shiller PE Ratio Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kiora Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiora Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Kiora Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Shiller PE Ratio falls into.



Kiora Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kiora Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Kiora Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.146/131.7762*131.7762
=3.146

Current CPI (Mar. 2024) = 131.7762.

Kiora Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -403.940 100.560 -529.335
201409 186.960 100.428 245.319
201412 -262.862 99.070 -349.642
201503 -8,665.069 99.621 -11,461.928
201506 -1,154.727 100.684 -1,511.319
201509 -914.157 100.392 -1,199.944
201512 -1,189.719 99.792 -1,571.028
201603 -1,503.243 100.470 -1,971.642
201606 -2,210.751 101.688 -2,864.882
201609 -1,732.095 101.861 -2,240.788
201612 -1,945.287 101.863 -2,516.550
201703 -1,413.711 102.862 -1,811.097
201706 -1,345.671 103.349 -1,715.810
201709 -1,087.336 104.136 -1,375.946
201712 -684.447 104.011 -867.156
201803 -613.113 105.290 -767.348
201806 -323.566 106.317 -401.049
201809 -333.202 106.507 -412.257
201812 -243.659 105.998 -302.916
201903 60.534 107.251 74.377
201906 -200.718 108.070 -244.749
201909 -375.912 108.329 -457.274
201912 -246.240 108.420 -299.286
202003 -140.094 108.902 -169.521
202006 -121.478 108.767 -147.176
202009 -134.482 109.815 -161.376
202012 -71.021 109.897 -85.161
202103 -81.648 111.754 -96.276
202106 -101.592 114.631 -116.787
202109 -86.751 115.734 -98.776
202112 -170.690 117.630 -191.218
202203 -92.098 121.301 -100.051
202206 -61.301 125.017 -64.615
202209 -54.813 125.227 -57.680
202212 -11.816 125.222 -12.434
202303 -8.406 127.348 -8.698
202306 -6.563 128.729 -6.718
202309 -7.505 129.860 -7.616
202312 -2.430 129.419 -2.474
202403 3.146 131.776 3.146

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kiora Pharmaceuticals  (FRA:7EY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Kiora Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiora Pharmaceuticals (FRA:7EY) Business Description

Traded in Other Exchanges
Address
332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.

Kiora Pharmaceuticals (FRA:7EY) Headlines

No Headlines